Evidence map›Paper›PMID 39919165›Full record

ArticleMolecular pharmacology2025

Evaluation of allosteric N-methyl-d-aspartate receptor modulation by GluN2A-selective antagonists using pharmacological equilibrium modeling.

James S Lotti, Jaron Jones, Jill C Farnsworth, Feng Yi, Fabao Zhao, Frank S Menniti, Robert A Volkmann, Rasmus P Clausen, Kasper B Hansen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

James S LottiCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana.
Jaron JonesCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana.
Jill C FarnsworthCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana.
Feng YiGuangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, Southern Medical University, Guangzhou, China.
Fabao ZhaoDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Frank S MennitiMindImmune Therapeutics, Inc, George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, Rhode Island.
Robert A VolkmannBioPharmaWorks, Groton, Connecticut.
Rasmus P ClausenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Kasper B HansenCenter for Structural and Functional Neuroscience, Center for Biomolecular Structure and Dynamics, Division of Biological Sciences, University of Montana, Missoula, Montana. Electronic address: kasper.hansen@umontana.edu.

Funding

Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP30GM140963 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2021 to 2025
$6.9M
Structural and functional investigation of negative allosteric NMDA receptor modulationR01NS097536 · NINDS · UNIVERSITY OF MONTANA · PI Kasper Boe Hansen · 2016 to 2026
$3.4M
NIGMS NIH HHS P30 GM140963NINDS NIH HHS R01 NS097536
6 · The paper itself

Abstract

N-methyl-d-aspartate (NMDA)-type ionotropic glutamate receptors are critically involved in excitatory neurotransmission and their dysfunction is implicated in many brain disorders. Allosteric modulators with selectivity for specific NMDA receptor subtypes are therefore attractive as therapeutic agents, and sustained drug discovery efforts have resulted in a wide range of new allosteric modulators. However, evaluation of allosteric NMDA receptor modulators is limited by the lack of operational ligand-receptor models to describe modulator binding dissociation constants (K

Indexed as

Receptors, N-Methyl-D-AspartateAllosteric RegulationAnimalsBenzenesulfonamidesGlycineHumansHydrazinesProtein BindingXenopus laevisBenzenesulfonamidesGlycineHydrazinesReceptors, N-Methyl-D-AspartateTCN 201Allosteric modulationDrug-receptor theoryElectrophysiologyIonotropic glutamate receptorLigand-gated ion channelNoncompetitive antagonism

Identifiers

PMID39919165
PMCPMC13095428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.